外用JAK抑制剂芦可替尼治疗白癜风
这项20周开放标签概念验证试验评估了每日两次外用1.5%芦可替尼乳膏治疗12例白癜风患者的效果。11例入组、9例完成,面部受累患者面部VASI改善76%,总体VASI改善23%,不良反应轻微。
要点
- 外用1.5%芦可替尼乳膏可使面部白癜风显著复色
- 总体VASI改善23%,躯干和肢端应答率较低
- 不良反应轻微,包括红斑、色素沉着和暂时性痤疮
核心结论
- 外用1.5%芦可替尼乳膏对 facial vitiligo 提供了显著复色,可能成为白癜风的有价值新疗法。
研究设计与样本
- 20周开放标签概念验证试验,每日两次外用1.5%芦可替尼乳膏,纳入至少1%体表面积受累的白癜风患者12例。
主要发现
- 11例入组,9例完成研究,54.5%为男性,平均年龄52岁。
- 8例患者中3例在躯干表面有应答,8例中1例在肢端表面有应答。
- 不良事件轻微,包括红斑、色素沉着和暂时性痤疮。
临床怎么用
- 对于面部受累的白癜风患者,可考虑尝试外用1.5%芦可替尼乳膏每日两次治疗。
局限性
- 样本量小且为开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing therapies for vitiligo are limited in efficacy and can be associated with undesirable side effects. Topical Janus kinase inhibitors may offer a new therapeutic option for vitiligo. OBJECTIVE: We sought to assess the role of topical ruxolitinib 1.5% cream, a Janus kinase inhibitor, in vitiligo treatment. METHODS: This 20-week, open-label, proof-of-concept trial of twice-daily topical ruxolitinib 1.5% cream was conducted in 12 patients with a minimum of 1% affected body surface area of vitiligo. The primary outcome was percent improvement in Vitiligo Area Scoring Index from baseline to week 20. RESULTS: Of 12 patients screened, 11 were enrolled and 9 completed the study (54.5% men; mean age, 52 years). Four patients with significant facial involvement at baseline had a 76% improvement in facial Vitiligo Area Scoring Index scores at week 20 (95% confidence interval, 53-99%; P = .001). A 23% improvement in overall Vitiligo Area Scoring Index scores was observed in all enrolled patients at week 20 (95% confidence interval, 4-43%; P = .02). Three of 8 patients responded on body surfaces and 1 of 8 patients responded on acral surfaces. Adverse events were minor, including erythema, hyperpigmentation, and transient acne. LIMITATIONS: Limitations of the study include the small sample size and open-label study design. CONCLUSIONS: Topical ruxolitinib 1.5% cream provided significant repigmentation in facial vitiligo and may offer a valuable new treatment for vitiligo.
引用
- Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017. PMID: 28390737. doi:10.1016/j.jaad.2017.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。